Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples